Loading... Please wait...

Our Newsletter


FG-4592 (ASP1517) | HIF prolyl-hydroxylase inhibitor

  • FG-4592.jpg
  • FG-4592, 400x400px, png
Price:
$79.00
Catalog #:
C3445-10
Quantity:


Product Description

FG-4592 is an orally-available isoquinoline-based inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase for the treatment of anemia and patients with chronic kidney disease. [1] Phase 2 studies indicate that oral administration of FG-4592 three times a week increased mean hemoglobin levels in the first eight weeks, regardless of supplementation with IV or oral iron, or no iron supplementation. FG-4592 is novel in that it allows integration of red blood cell production and efficient iron incorporation simultaneously. [1]

Data from Phase 2 trials comparing with epoetin alpha indicate that treatment with FG-4592 alone results in a sustained reduction of total plasma cholesterol levels by an average of 20%, while no reduction was seen with epoetin alpha. [2, 3]

In December, 2012, Fibrogen and Astellas Pharma announced the initiation of a Phase 3 clinical development program for the treatment of anemia associated with chronic kidney disease in patients not on dialysis and on dialysis. [4]


Technical information:

Chemical Formula:   C19H16N2O5
CAS #:   808118-40-3
Molecular Weight:   352.34
Purity:   > 98%
Appearance:   Yellow
Chemical Name:   2-(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxamido)acetic acid
Solubility:   Up to 100 mM in DMSO
Synonyms:   FG-4592, FG4592, ASP1517

Shipping Condition: The product is shipped in a glass vial at ambient temperature.
Storage condition: For longer shelf life, store solid powder at 4oC desiccated, or store DMSO solution at -20oC.


Reference:

1. "Correction of anemia without IV iron supplementation in incident dialysis patients" Fibrogen press release, Nov. 5, 2012
2. "FG-4592 and epoetin alpha in Phase II anemia study", Datamonitor Research Store, Nov. 11, 1012.
3. "Hemoglobin correction and maintenance in end-stage renal patients" Fibrogen press release, Nov. 5, 2012
4. Fibrogen press release, Dec. 11, 2012 (Phase 3 announcement)

Other Information:

Product Specification (pdf)
MSDS (pdf)
Certificate of Analysis is available upon request.

Write your own product review

Product Reviews

This product hasn't received any reviews yet. Be the first to review this product!

Add to Wish List

Click the button below to add the FG-4592 (ASP1517) | HIF prolyl-hydroxylase inhibitor to your wish list.

You Recently Viewed...